All fields are required.

Close Appointment form

About Bioserve

About BioServe

Our ‘biomaterial to data’ model offers one of the world’s largest commercial biorepositories of tissue samples. We also offer full suite of preclinical molecular services, like high quality genotyping services, and research tools to accelerate breakthroughs in genetics, drug discovery, biomarker research, and molecular diagnostics.

tissue-bank

BioServe’s Global BioRepository provides leading academic and industry researchers with access to over 600,000 human DNA, serum and tissue samples linked to detailed clinical and demographic data from 120,000 consented and anonymized patients on four continents.

Utilizing BioServe’s preclinical molecular services like our genotyping services, researchers can identify genetic markers, validate drug targets and correlate clinical and molecular data to accelerate the development of new and safer drugs.

BioServe’s customers include nearly every major pharmaceutical and biotechnology company, as well as top industry, academic, and government research institutions.

Founded in 1989, BioServe has corporate headquarters in Beltsville, Maryland and Hyderabad, India.

How we got here

2012
The Ventyx Wesley Research Institute Tissue Bank Joins the BioServe Network
2010
BioServe Europe founded in August
Formed BioServe Network
2009
Upgraded current facility laboratory space to current 21,000 square feet footprint
2007
Acquired assets of Genomics Collaborative, Inc. from SeraCare
Relocated to current facility in Beltsville, Maryland
Obtained CLIA certification
2006
Expanded high-throughput genotyping capabilities with iPlex platform from Sequenom
BioServe India relocates to expanded laboratory facility (14,000 sq. ft.
2003
Acquired assets of Qiagenomics in Seattle, Washington
2002
BioServe India founded in Hyderabad, India
2001
Renewal of NIEHS contract for an additional 5 years
Integrated high-throughput genotyping capabilities into services (Sequenom)
2000
BioServe presents three abstracts and one oral mini-symposium on p53 at annual meeting of American Association for Cancer Research (AACR) in Philadelphia
1998
BioServe integrates real-time PCR platform into services line (ABI)
1997
BioServe upgrades to high-throughput DNA synthesizer platforms
1996
BioServe expands laboratory space from 5,000 square feet to 12,000 square feet in Laurel facility
1995
BioServe secures first multi-year contract with National Institutes of Environmental Health Sciences (NIEHS)
1994
BioServe obtains three SBIR grants for fingerprinting in breast and prostate cancer, as well as detection of RAS mutations using LCR
1993
BioServe secures first Small Business Innovation Research (SBIR) grant for sub-typing HPV in oral cancers
1992
BioServe graduates from TAP and re-locates to facility in Laurel, Maryland
1991
BioServe secures first blanket purchase order agreement with NIH
1990
January 5 – BioServe officially incorporated as a business
1989
October 7 -BioServe founded by researchers who left National Cancer Institute with funding from the University of Maryland Technology Advancement Program (TAP)

Human Samples / Molecular Services Inquiry

CLOSE